Granted Patent B2

US 8,545,890 · App. 12/270,905 · Granted Oct 1, 2013

Abstract

Claims (15)

1. A composite excipient consisting of calcium silicate particles substantially completely covered by and in contact with mannitol.

2. The composite of claim 1 wherein the calcium silicate comprises about 5% to about 50% of the composite by weight, and the mannitol comprises about 50% to about 95% of the composite by weight.

3. The composite excipient of claim 1 wherein the calcium silicate comprises about 25% of the composite by weight, and the mannitol comprises about 75% of the composite by weight.

4. The composite excipient of claim 1 wherein the composite excipient has an average particle size of at least about 50 micrometers.

5. A method of making the composite excipient, the method comprising:

adding mannitol to water;

heating the solution to a temperature at which mannitol is substantially dissolved to form a solution;

adding calcium silicate with stirring to the solution to form a slurry;

drying the slurry in a heated air stream to form calcium silicate that is substantially completely covered by and in contact with mannitol.

6. An orally disintegrating tablet comprising:

a. at least one pharmaceutically active ingredient or nutraceutical; and

b. a composite excipient consisting of calcium silicate particles substantially completely covered by and in contact with mannitol, whereby the calcium silicate is prevented from reacting with the active pharmaceutical ingredient.

7. The orally disintegrating tablet of claim 6 further including a salivating agent.

8. The orally disintegrating tablet of claim 6 wherein the calcium silicate comprises about 5% to about 50% of the composite excipient by weight, and the mannitol comprises about 50% to about 95% of the composite excipient by weight.

9. The orally disintegrating tablet of claim 6 wherein the composite excipient has an average particle size of at least about 50 micrometers.

Assignments (9)